Hetero, Cipla get gesture to make, market antiviral medication remdesivir Kumar Jeetendra | June 21, 2020 India’s Drug Regulator on June 20 allowed to Hetero and Cipla to produce and market antiviral medication remdesivir for “confined crisis use” on hospitalized COVID-19 patients, official sources said. This comes a day after the Drug Controller General of India (DCGI), thinking about the crisis and neglected requirement for medications considering the coronavirus episode, allowed …
